Bliss GVS Pharma Limited (NSE:BLISSGVS)
India
· Delayed Price · Currency is INR | Market Cap | 12.45B |
| Revenue (ttm) | 8.10B |
| Net Income (ttm) | 596.13M |
| Shares Out | n/a |
| EPS (ttm) | 5.62 |
| PE Ratio | 20.89 |
| Forward PE | n/a |
| Dividend | 0.50 (0.40%) |
| Ex-Dividend Date | Jul 18, 2024 |
| Volume | 376,268 |
| Average Volume | 571,041 |
| Open | 119.60 |
| Previous Close | 118.61 |
| Day's Range | 116.00 - 120.38 |
| 52-Week Range | 92.15 - 185.50 |
| Beta | 0.90 |
| RSI | 35.01 |
| Earnings Date | Apr 30, 2025 |
About Bliss GVS Pharma
Bliss GVS Pharma Limited develops, manufactures, and markets pharmaceutical formulations in India and internationally. The company offers pharma products, including capsules, creams/gels/ointments, dry powder for injections and oral suspensions, effervescent tablets, eye/ear drops, injections, liquid preparations, lozenges, nasal solutions, oral solids, parenterals, pessaries, sachets, soft gelatin capsules, suppositories, suspensions, topical preparations, and transdermal patches. It also provides other healthcare products, such as balms, nasa... [Read more]
Financial Performance
In 2023, Bliss GVS Pharma's revenue was 7.70 billion, an increase of 2.48% compared to the previous year's 7.52 billion. Earnings were 754.54 million, an increase of 6.49%.
Financial StatementsNews
Bliss GVS Pharma shares surge 4% after company receives GMP Compliance certification for its manufacturing facilities in Palghar
Bliss GVS Pharma’s stock rose 4% in morning trade after the company received a GMP (Good Manufacturing Practice) Compliance Certificate. This certification was granted after a rigorous inspection by R...
Bliss GVS Pharma receives GMP Compliance certification for manufacturing facilities in Palghar, Maharashtra
Bliss GVS Pharma Limited has recently informed exchanges that the company received a GMP (Good Manufacturing Practice) Compliance Certificate. This recognition comes after a comprehensive inspection c...